GE HealthCare Unveils AI-Powered Breast Cancer Detection Technology
The system, designed to enhance sensitivity in detecting invasive cancer, offers advanced imaging features that could support early-stage cancer identification while minimizing unnecessary procedures.
GE HealthCare has introduced the Invenia Automated Breast Ultrasound (ABUS) Premium, a 3D ultrasound system integrated with artificial intelligence (AI), aimed at improving supplemental screening and streamlining exam readings for patients with dense breasts.
The system, designed to enhance sensitivity in detecting invasive cancer, offers advanced imaging features that could support early-stage cancer identification while minimizing unnecessary procedures.
Enhanced Imaging and Faster Screening
The Invenia ABUS Premium incorporates AI-driven Verisound tools, including Scan Quality Assessment for real-time evaluation of breast coverage and positioning, as well as Auto Nipple Detection for consistent marker positioning. The newly introduced Fast Scan tool is designed to speed up scans by 40%, while the cSound Imageformer technology ensures high-resolution image quality by automatically focusing at every pixel.
According to GE HealthCare, the technology not only enhances image clarity but also assists in distinguishing malignant tumors, potentially reducing the need for unnecessary biopsies. Unlike traditional screening methods, it eliminates patient exposure to iodinated contrast agents or ionizing radiation.
Clinical Benefits and Patient-Centric Approach
Karley Yoder, CEO of Comprehensive Care Ultrasound at GE HealthCare, emphasized the potential impact of the technology on clinical outcomes.
"Women with dense breasts often face poorer outcomes due to malignancies detected at later, more advanced stages. Invenia ABUS Premium equipped with AI has the potential to optimize clinicians’ screening capabilities, enabling them to detect even small, early-stage cancers with a high degree of confidence in women with dense breasts," Yoder stated.
The system features a Reverse Curve transducer designed to follow the natural contour of the breast, while adjustable compression levels provide a more personalized and comfortable experience during the exam.
The Invenia ABUS Premium has received U.S. Food and Drug Administration (FDA) premarket approval and is set to launch in key markets throughout the year.
